Preclinical blockade of DDR1 restructures collagen, enhances CD8+ T cell penetration, and suppresses tumor growth [10,12]; monoclonal antibodies against the DDR1-ECD can even induce complete tumor regression while boosting interferon-γ (IFN-γ) production [10,13]. Here, CD8A is linked to neoplasm.